Business, Science Clash at Medical Journal (washingtonpost.com)
This article discusses a situation in which an editorial whose questions were valid and timely was rejected due to marketing concerns, not scholarship. Apparently there was a concern that in publishing it, the journal would offend a major drug company/advertiser.
Knowledge is power, but unfortunately, so is money.
A followup appears in the news extra of this week's BMJ. Apparently the journal, Dialysis & Transplantation, reversed its original stance, but the author has declined to resubmit it for consideration.
Kudos to the author for blowing the whistle on this by publicising the rejection e-mail. :) One good thing about the Internet is that it helps keep accountability by allowing nearly-instant fallout.
No comments:
Post a Comment